Gene Biodesign Certified to Provide NimbleGen Array Services in Taiwan
"As the latest Roche NimbleGen CSP, Gene Biodesign has made a significant investment in cutting-edge genetic analysis technologies and will provide support for these technologies in Asia," said Jessica Chen, CEO of Gene Biodesign. "We feel we offer a superb value proposition in that we can provide certified services to academic and clinical research segments alike. We hope this collaborative effort will result in a new era of genomic studies for the life sciences and human public health."
Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc., added, "Roche NimbleGen is extremely excited to welcome Gene Biodesign to our family of certified service providers in Asia, where they will support the entire portfolio of NimbleGen array applications. We are confident that adding Gene Biodesign to the program will be a major factor in achieving high growth for Roche NimbleGen in Taiwan, as well as throughout Asia."
For more information about Roche NimbleGen, please visit www.nimblegen.com
About Gene Biodesign Enterprises Co.
Gene Biodesign is not only a leading services provider in the microarray technology, but also a professional provider in scientific equipment. Gene Biodesign is an important distributor of analytical instrumentation in Taiwan and offers a wide range of products for genomics, proteomics and bioinformatics. With our core value of "quality" our team of professional and enthusiastic employees at Gene Biodesign is eager to provide customers with the highest quality services and products. Our mission is to help our customers find opportunities for research and advanced study in life sciences and human public health.
For life science research only. Not for use in diagnostic procedures.
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.